1. Home
  2. OMCL vs CAPR Comparison

OMCL vs CAPR Comparison

Compare OMCL & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omnicell Inc. ($0.001 par value)

OMCL

Omnicell Inc. ($0.001 par value)

HOLD

Current Price

$44.34

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.89

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMCL
CAPR
Founded
1992
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.3B
IPO Year
2000
2011

Fundamental Metrics

Financial Performance
Metric
OMCL
CAPR
Price
$44.34
$28.89
Analyst Decision
Buy
Strong Buy
Analyst Count
6
8
Target Price
$55.83
$44.63
AVG Volume (30 Days)
605.7K
1.1M
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.25
N/A
Revenue
$787,309,000.00
N/A
Revenue This Year
$6.77
N/A
Revenue Next Year
$5.22
$3.31
P/E Ratio
$174.48
N/A
Revenue Growth
9.93
N/A
52 Week Low
$26.85
$4.30
52 Week High
$51.84
$40.37

Technical Indicators

Market Signals
Indicator
OMCL
CAPR
Relative Strength Index (RSI) 60.98 42.38
Support Level $44.17 $27.98
Resistance Level $45.17 $30.06
Average True Range (ATR) 1.43 1.87
MACD -0.13 -0.39
Stochastic Oscillator 68.90 26.58

Price Performance

Historical Comparison
OMCL
CAPR

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: